Skip to main content
Erschienen in: BMC Women's Health 1/2024

Open Access 01.12.2024 | Correction

Correction: Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis

verfasst von: Daniel Figueiredo, Inês Ribeiro, Ana Penedones, Diogo Mendes, Carlos Alves, Francisco Batel-Marques, Daniel Pereira da Silva

Erschienen in: BMC Women's Health | Ausgabe 1/2024

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The online version of the original article can be found at https://​doi.​org/​10.​1186/​s12905-023-02219-0.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
BMC Women’s Health (2023) 23:96
Following publication of the original article [1], the text need to be added in the acknowledgement section “Óscar Lourenço, whose affiliation is Univ. Coimbra, CeBER, Faculty of Economics, Av. Dias da Silva 165, 3004 − 512 Coimbra, has participated in the elaboration of this paper and should be considered as an author. He was not included in the author list due to an unnoticed error”. So, the acknowledgement section will read as “The authors would like to acknowledge to the expert panel members who kindly accepted to participate in this work: Dra. Olga Ilheu, Dra. Amélia Pedro, Dr. José Moutinho, Dra. Fernanda Loureiro, Dra. Paula Borralho, and Dra. Ana Quintas. D. Figueiredo acknowledges the support of CIDMA through the Portuguese Foundation for Science and Technology (UIDB/04106/2020). Óscar Lourenço, whose affiliation is Univ. Coimbra, CeBER, Faculty of Economics, Av. Dias da Silva 165, 3004 − 512 Coimbra, has participated in the elaboration of this paper and should be considered as an author. He was not included in the author list due to an unnoticed error.”
The original article has been corrected.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
Correction: Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis
verfasst von
Daniel Figueiredo
Inês Ribeiro
Ana Penedones
Diogo Mendes
Carlos Alves
Francisco Batel-Marques
Daniel Pereira da Silva
Publikationsdatum
01.12.2024
Verlag
BioMed Central
Erschienen in
BMC Women's Health / Ausgabe 1/2024
Elektronische ISSN: 1472-6874
DOI
https://doi.org/10.1186/s12905-024-02927-1

Weitere Artikel der Ausgabe 1/2024

BMC Women's Health 1/2024 Zur Ausgabe

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.